Docoh
Loading...

24 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
and processing charges. If you attend the meeting, you may revoke your proxy and vote in person. In light of the COVID-19 pandemic, it could become necessary
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
and vote in person. In light of the COVID-19 pandemic, it could become necessary to change the date, time, location and/or means of holding the Special
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
pandemic on our business, operations or ability to obtain funding; our ability to obtain and maintain regulatory approval of our product candidates; our … pandemic on our business, operations or ability to obtain funding; our ability to obtain and maintain regulatory approval of our product candidates
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
by a Phase 1B maximum tolerated dose trial. Impact of COVID-19 The extent of the impact of the COVID-19 pandemic on our business, operations … . Although we modified our operations and practices in 2020 due to the COVID-19 pandemic and to comply with federal, state and local requirements, our business
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
ability to obtain funding for our future operations; the impact of the COVID-19 pandemic on our business, operations or ability to obtain funding; our
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
in this Agreement, and no Party shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, pandemic, explosion, fire, flood
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, including the impact of the COVID-19 pandemic
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
The extent of the impact of the COVID-19 pandemic on our business, operations and development timelines and plans remains uncertain, and will depend … and our key scientific and management personnel. Although we modified our operations and practices in 2020 due to the COVID-19 pandemic and to comply
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
that the Company’s principal executive offices are closed during such period due to the ongoing COVID-19 pandemic, stockholders wishing to examine … and World Health Organization may recommend or impose for the coronavirus (COVID-19) pandemic. In the event it is not possible, prudent, or advisable
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
, but are not limited to, statements about: our ability to obtain funding for our operations; the impact of the COVID-19 pandemic on our business
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
: our ability to obtain funding for our operations; the impact of the COVID-19 pandemic on our business, operations or ability to obtain funding; our
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
, but are not limited to, the following: our ability to obtain funding for our future operations; the impact of the COVID-19 pandemic on our business, operations … pandemic or another pandemic may disrupt our operations and affect our ability to successfully conduct clinical studies and raise capital. The COVID-19
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
, 2020, the World Health Organization declared the outbreak of the SARS-CoV-2 virus to be a global pandemic. Our clinical development timelines and plans … could be affected by the SARS-CoV-2 virus pandemic. Site initiation and patient enrollment could be delayed or suspended due to prioritization
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
-19 pandemic. PCS499 Our lead product, PCS499, is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX … COVID-19 pandemic. This PCS499 NL study will be a randomized, placebo-controlled Phase 2B study to better understand the potential response of NL
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
trial for PCS499, however, the finalization of the trial data and its closeout has been delayed due to the ongoing COVID-19 pandemic. PCS499 Our lead … -controlled trial in the fourth quarter of 2020, but we now expect to begin recruiting patients in 2021 due to the ongoing COVID-19 pandemic. This PCS499
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
, the finalization of the trial data and its closeout has been delayed due to the ongoing COVID-19 pandemic. PCS499 Our lead product, PCS499 … in the fourth quarter of 2020, but we now expect to begin recruiting patients in 2021 due to the ongoing COVID-19 pandemic. This PCS499 NL study
S-1/A
EX-10.13
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, explosion, fire, flood, tornadoes, pandemic
S-1/A
EX-10.11
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
is due to a pandemic, natural disaster, explosion, fire, flood, tornadoes, thunderstorms, earthquake, war, terrorism, riots, embargo, losses
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, explosion, fire, flood, tornadoes, pandemic
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
is due to a pandemic, natural disaster, explosion, fire, flood, tornadoes, thunderstorms, earthquake, war, terrorism, riots, embargo, losses